Portal de investigación
The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- Chen B
- Wang J
- Pu X
- Li J
- Wang Q
- Liu L
- Xu Y
- Xu L
- Kong Y
- Li K
- Xu F
- Liang S
- Wu L
Grupos de investigación
Resumen
Background: Although immune checkpoint inhibitor (ICI) monotherapy remains the standard of second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) , the objective response rate (ORR) is low. There is an urgent need to increase the response population of second-line immunotherapy, and ICI combination therapy may be a possible option. However, the evidence is insufficient. Methods: We retrospectively collected the medical records of patients who received ICI monotherapy or ICI combination therapy as a second-line or later treatment option. We further analysed baseline clinical characteristics, evaluated treatment efficacy, assessed treatment-related adverse events (AEs) and followed up survival. The outcome variables assessed in the study were ORR, disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and AEs. Results: A total of 145 patients were ultimately enrolled in this study, including the ICI monotherapy group (n=63) and ICI combination therapy group (n=82). The ICI combination therapy group was further divided into the ICI/chemotherapy group (n=57) and ICI/anti-angiogenic therapy group (n=25). The baseline was comparable among the three subgroups. The ICI combination therapy groups showed a higher ORR (29.3% vs. 11.1%, P=0.008) and DCR (85.4% vs. 61.9%, P=0.001) and a longer PFS (6.77 vs. 3.47 months, P<0.001) and OS (18.60 vs. 8.47 months, P<0.001) than the ICI monotherapy group. The ICI/chemotherapy group showed a significantly higher ORR (31.6% vs. 11.1%, P=0.006) and DCR (84.2% vs. 61.9%, P=0.006) and a longer PFS (6.37 vs. 3.47 months, P<0.001) and OS (18.60 vs. 8.47 months, P<0.001) than the ICI monotherapy group. The ICI/anti-angiogenic therapy group showed a significantly higher DCR (88.0% vs. 61.9%, P=0.021) and a longer PFS (8.17 vs. 3.47 months, P<0.001) and OS (19.20 vs. 8.47 months, P=0.005) than the ICI monotherapy group. Neither of the combined ICI therapy groups showed a significant increase in the incidence of AEs compared to the ICI monotherapy group. Conclusions: ICI combined with chemotherapy or anti-angiogenic therapy as second-line or later treatment demonstrated superiority over ICI monotherapy in advanced NSCLC patients without prior immunotherapy. These results provide a potentially superior treatment strategy and require verification in prospective clinical trials. © 2022 AME Publishing Company. All rights reserved.
2022 Translational Lung Cancer Research. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 2218-6751, 2226-4477
- Tipo:
- Article
- Páginas:
- 2111-2124
- DOI:
- 10.21037/tlcr-22-697
- Enlace a otro recurso:
- www.scopus.com
Translational Lung Cancer Research AME Publishing Company
Citas Recibidas en Web of Science: 2
Citas Recibidas en Scopus: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- alanine aminotransferase; amylase; angiogenesis inhibitor; antineoplastic agent; antineoplastic metal complex; aspartate aminotransferase; bevacizumab; camrelizumab; catequentinib; docetaxel; gemcitabine; immune checkpoint inhibitor; nivolumab; paclitaxel; pembrolizumab; pemetrexed; programmed death 1 ligand 1; sintilimab; toripalimab; triacylglycerol lipase; adult; advanced cancer; aged; anemia; antiangiogenic therapy; Article; cancer chemotherapy; cancer patient; cancer survival; clinical feature; cohort analysis; comparative study; disease control; drug efficacy; drug safety; female; follow up; human; hyperthyroidism; hypopituitarism; hypothyroidism; incidence; leukopenia; major clinical study; male; median survival time; monotherapy; myocarditis; nausea; neutropenia; non small cell lung cancer; outcome assessment; outcome variable; overall response rate; overall survival; pneumonia; progression free survival; prospective study; rash; retrospective study; side effect; thrombocytopen
Proyectos asociados
Citar la publicación
Chen B,Wang J,Pu X,Li J,Wang Q,Liu L,Xu Y,Xu L,Kong Y,Li K,Xu F,Liang S,Cardona AF,Wu L. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study. Transl Lung Cancer Res. 2022. 11. (10):p. 2111-2124. IF:4,000. (2).